T1562

Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.

JNJ-54175446 (JNJ-5446) is a CNS-permeable and selective P2X7 receptor antagonist that attenuates the release of IL-1β/IL-18 from microglia, and may be used in the study of depression.

JT010 is an effective agonist of TRPA1 (EC50 = 0.65 nM).

JNJ-5207787 is a blood–brain barrier penetrant neuropeptide Y Y2 receptor antagonist that demonstrates greater than 100-fold selectivity over Y1, Y4, and Y5 receptor subtypes, JNJ-5207787 potently suppresses peptide YY binding at both human and rat Y2 receptors, supporting the use of JNJ-5207787 in central nervous system research focused on neuropeptide signaling.

Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.

JNJ-61432059 is an orally active and selective negative modulator of TARP γ-8 selective AMPAR (pIC50: 9.7).

JNJ-64619178 is a selective, orally active, and pseudo-irreversible inhibitor of protein arginine methyltransferase 5 (IC50: 0.14 nM). It has effective activity In lung cancer.

JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).

JPM-OEt is a broad-spectrum cysteine cathepsin inhibitor with antitumor activity that binds covalently at the active site, irreversibly inhibiting the cysteine cathepsin family.

(S)-JQ-35 (TEN-010) is a BET bromodomain inhibitor with anti-tumor activity, particularly in breast cancer research.

JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).

Rebamipide-D4 is deuterium labeled Rebamipide (T1562).